

Recent Publications 2010-2012

Recent Publications 2010-2012

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, Voeltz MD, Chandna H, Ramaiah C, Brtko M, Cannon L, Dyke C, Liu T, Montalescot G, Manoukian SV, Prats J, Topol EJ; BRIDGE Investigators.
JAMA. 2012 Jan 18;307(3):265-74.

Left atrial appendage occlusion for the reduction of stroke and embolism in patients with atrial fibrillation.
Gibson DN, Price MJ, Ahern TS, Teirstein PS.
J Cardiovasc Med (Hagerstown). 2012 Feb;13(2):131-7.

Platelet-mediated thrombosis and drug-eluting stents.
Granada JF, Price MJ, French PA, Steinhubl SR, Cutlip DE, Becker RC, Smyth SS, Dauerman HL.
Circ Cardiovasc Interv. 2011 Dec 1;4(6):629-37.

The brave new world of antiplatelet therapy: seeking clarity in a world of increasing choice and complexity.
Price MJ.
Rev Cardiovasc Med. 2011;12 Suppl 1:S1-3.

Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.
Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, Patti G, Breet NJ, DiSciascio G, Cuisset T, Dangas G.
J Am Coll Cardiol. 2011 Nov 1;58(19):1945-54.

Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ.
Circulation. 2011 Sep 6;124(10):1132-7.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
Price MJ, Tantry US, Gurbel PA.
Rev Cardiovasc Med. 2011;12(1):1-12.

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators.
JAMA. 2011 Mar 16;305(11):1097-105.

Clinical outcomes following predilation with a novel 1.25-mm diameter angioplasty catheter.
Kandzari DE, Zankar AA, Teirstein PS, Brilakis ES, Banerjee S, Price MJ, Stinis CT, Hudson PA, Dahle TG, Eng M, Brown R, Ferguson A, Addo TA, Popma JJ.
Catheter Cardiovasc Interv. 2011 Mar 1;77(4):510-4.

Recent Publications 2010–2012

Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists.

Price MJ, Barker CM.

Biomark Med. 2011 Feb;5(1):43-51.

Intraprocedural stent thrombosis during crush stenting of the left main coronary artery bifurcation.

Nayak KR, Mehta HS, Barker CM, Price MJ.

Tex Heart Inst J. 2010;37(5):616-7.

Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity.

Barker CM, Murray SS, Teirstein PS, Kandzari DE, Topol EJ, Price MJ.

JACC Cardiovasc Interv. 2010 Oct;3(10):1001-7.

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. Working Group on High On-Treatment Platelet Reactivity.

Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA;

J Am Coll Cardiol. 2010 Sep 14;56(12):919-33.

Longer-term outcomes of paclitaxel stent implantation as an initial treatment strategy for sirolimus-eluting stent restenosis.

Levisay JP, Price MJ, Shaba W, Lee SS, Stinis CP, Miller L, Teirstein PS.

J Invasive Cardiol. 2010 May;22(5):216-9.

The evidence base for platelet function testing in patients undergoing percutaneous coronary intervention.

Price MJ.

Circ Cardiovasc Interv. 2010 Jun 1;3(3):277-83; discussion 283. No abstract available.

A novel technique for ultra-low contrast administration during angiography or intervention.

Nayak KR, Mehta HS, Price MJ, Russo RJ, Stinis CT, Moses JW, Mehran R, Leon MB, Kandzari DE, Teirstein PS.

Catheter Cardiovasc Interv. 2010 Jun 1;75(7):1076-83.

Identifying the "optimal" duration of dual antiplatelet therapy after drug-eluting stent revascularization.

Kandzari DE, Angiolillo DJ, Price MJ, Teirstein PS.

JACC Cardiovasc Interv. 2009 Dec;2(12):1279-85.

Utility of on-line three-dimensional transesophageal echocardiography during percutaneous atrial septal defect closure.

Price MJ, Smith MR, Rubenson DS.

Catheter Cardiovasc Interv. 2010 Mar 1;75(4):570-7.

The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.

Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, Steg PG, Montalescot G, Bhakta N, Hacke W, Flather MD, Mak KH, Cacoub P, Creager MA, Berger PB, Steinhubl SR, Murugesan G, Mehta SR, Kottke-Marchant K, Lincoff AM, Topol EJ; on behalf of the CHARISMA Investigators.

Eur Heart J. 2012 Mar 26.

Recent Publications 2010–2012

Characterization of circulating endothelial cells in acute myocardial infarction.

Damani S, Bacconi A, Libiger O, Chourasia AH, Serry R, Gollapudi R, Goldberg R, Rapeport K, Haaser S, Topol S, Knowlton S, Bethel K, Kuhn P, Wood M, Carragher B, Schork NJ, Jiang J, Rao C, Connelly M, Fowler VM, Topol EJ. *Sci Transl Med.* 2012 Mar 21;4(126):126ra33.

Whole Blood Gene Expression Testing for Coronary Artery Disease in Nondiabetic Patients: Major Adverse Cardiovascular Events and Interventions in the PREDICT Trial.

Rosenberg S, Elashoff MR, Lieu HD, Brown BO, Kraus WE, Schwartz RS, Voros S, Ellis SG, Waksman R, McPherson JA, Lansky AJ, Topol EJ; for the PREDICT Investigators. *J Cardiovasc Transl Res.* 2012 Mar 7.

Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.

Good CW, Steinhubl SR, Brennan DM, Lincoff AM, Topol EJ, Berger PB. *Circ Cardiovasc Interv.* 2012 Feb 1;5(1):77-81.

Dual or Mono Antiplatelet Therapy for Patients With Acute Ischemic Stroke or Transient Ischemic Attack: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Geeganage CM, Diener HC, Algra A, Chen C, Topol EJ, Dengler R, Markus HS, Bath MW, Bath PM; for the Acute Antiplatelet Stroke Trialists Collaboration. *Stroke.* 2012 Apr;43(4):1058-1066.

The unmet need of education in genomic medicine.

Patay BA, Topol EJ. *Am J Med.* 2012 Jan;125(1):5-6.

Comparative gene expression analysis between coronary arteries and internal mammary arteries identifies a role for the TES gene in endothelial cell functions relevant to coronary artery disease.

Archacki SR, Angheloiu G, Moravec CS, Liu H, Topol EJ, Wang QK. *Hum Mol Genet.* 2012 Mar 15;21(6):1364-73. Epub 2011 Dec 12.

Association of direct-to-consumer genome-wide disease risk estimates and self-reported disease.

Bloss CS, Topol EJ, Schork NJ. *Genet Epidemiol.* 2011 Nov 29. doi: 10.1002/gepi.20664.

Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis.

Mehta RH, Stebbins AS, Lopes RD, Califf RM, Pieper KS, Armstrong PW, Van de Werf F, Hochman JS, White HD, Topol EJ, Alexander JH, Granger CB. *Am J Cardiol.* 2012 Feb 1;109(3):320-6.

Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.

Berger JS, Bhatt DL, Steg PG, Steinhubl SR, Montalescot G, Shao M, Hacke W, Fox KA, Berger PB, Topol EJ, Lincoff AM. *Am Heart J.* 2011 Jul;162(1):98-105.e1.

Recent Publications 2010–2012

Is pocket mobile echocardiography the next-generation stethoscope? A cross-sectional comparison of rapidly acquired images with standard transthoracic echocardiography.

Liebo MJ, Israel RL, Lillie EO, Smith MR, Rubenson DS, Topol EJ.

Ann Intern Med. 2011 Jul 5;155(1):33-8.

Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials.

Kereiakes DJ, Popma JJ, Cannon LA, Kandzari DE, Kimmelstiel CD, Meredith IT, Teirstein PS, Verheye S, Allocco DJ, Dawkins KD, Stone GW.

EuroIntervention. 2012 Mar 25.

Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement.

Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, Fontana GP, Dewey TM, Thourani VH, Pichard AD, Fischbein M, Szeto WY, Lim S, Greason KL, Teirstein PS, Malaisrie SC, Douglas PS, Hahn RT, Whisenant B, Zajarias A, Wang D, Akin JJ, Anderson WN, Leon MB; the PARTNER Trial Investigators.

N Engl J Med. 2012 Mar 26.

Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial.

Alli OO, Teirstein PS, Satler L, Sketch MH Jr, Popma JJ, Mauri L, Wang HP, Schleckser PA, Cohen SA, Holmes DR Jr.

Am Heart J. 2012 Mar;163(3):438-45.

Percutaneous coronary intervention use in the United States: defining measures of appropriateness.

Marso SP, Teirstein PS, Kereiakes DJ, Moses J, Lasala J, Grantham JA.

JACC Cardiovasc Interv. 2012 Feb;5(2):229-35. Epub 2012 Feb 8.

PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses.

Meredith IT, Whitbourn R, Scott D, El-Jack S, Zambahari R, Stone GW, Teirstein PS, Starzyk RM, Allocco DJ, Dawkins KD.

EuroIntervention. 2011 May;7(1):84-90.

Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients.

Gale AJ, Elias DJ, Averell PM, Teirstein PS, Buck M, Brown SD, Polonskaya Z, Udit AK, Finn MG.

Thromb Res. 2011 Oct;128(4):e9-13.

A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial.

Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco DJ, Dawkins KD; PLATINUM Trial Investigators.

J Am Coll Cardiol. 2011 Apr 19;57(16):1700-8.

Clinical outcomes following predilation with a novel 1.25-mm diameter angioplasty catheter.

Kandzari DE, Zankar AA, Teirstein PS, Brilakis ES, Banerjee S, Price MJ, Stinis CT, Hudson PA, Dahle TG, Eng M, Brown R, Ferguson A, Addo TA, Popma JJ.

Catheter Cardiovasc Interv. 2011 Mar 1;77(4):510-4.

Recent Publications 2010–2012

Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity.

Barker CM, Murray SS, Teirstein PS, Kandzari DE, Topol EJ, Price MJ.

JACC Cardiovasc Interv. 2010 Oct;3(10):1001-7.

Drug-eluting stent restenosis: an uncommon yet pervasive problem.

Teirstein PS.

Circulation. 2010 Jul 6;122(1):5-7.

Comparison of long-term (4-year) outcomes of patients with unprotected left main coronary artery narrowing treated with drug-eluting stents versus coronary-artery bypass grafting.

Wu X, Chen Y, Liu H, Teirstein PS, Kirtane AJ, Ge C, Song X, Chen X, Gu C, Huang F, Lv S.

Am J Cardiol. 2010 Jun 15;105(12):1728-34.

Longer-term outcomes of paclitaxel stent implantation as an initial treatment strategy for sirolimus-eluting stent restenosis.

Levisay JP, Price MJ, Shaba W, Lee SS, Stinis CP, Miller L, Teirstein PS.

J Invasive Cardiol. 2010 May;22(5):216-9.

A novel technique for ultra-low contrast administration during angiography or intervention.

Nayak KR, Mehta HS, Price MJ, Russo RJ, Stinis CT, Moses JW, Mehran R, Leon MB, Kandzari DE, Teirstein PS.

Catheter Cardiovasc Interv. 2010 Jun 1;75(7):1076-83.

Identifying the "optimal" duration of dual antiplatelet therapy after drug-eluting stent revascularization.

Kandzari DE, Angiolillo DJ, Price MJ, Teirstein PS.

JACC Cardiovasc Interv. 2009 Dec;2(12):1279-85.

Dual catheter technique for the treatment of severe coronary artery perforations.

Ben-Gal Y, Weisz G, Collins MB, Genereux P, Dangas GD, Teirstein PS, Singh VP, Rabbani LE, Kodali SK, Sherman W, Leon MB, Moses JW.

Catheter Cardiovasc Interv. 2010 Apr 1;75(5):708-12.

A randomized controlled trial of angiography versus intravascular ultrasound-directed bare-metal coronary stent placement (the AVID Trial).

Russo RJ, Silva PD, Teirstein PS, Attubato MJ, Davidson CJ, DeFranco AC, Fitzgerald PJ, Goldberg SL, Hermiller JB, Leon MB, Ling FS, Lucisano JE, Schatz RA, Wong SC, Weissman NJ, Zientek DM; AVID Investigators.

Circ Cardiovasc Interv. 2009 Apr;2(2):113-23.

Change we can believe in: the hyper-evolution of percutaneous coronary intervention for unprotected left main disease with drug-eluting stents.

Price MJ, Kandzari DE, Teirstein PS.

Circ Cardiovasc Interv. 2008 Dec;1(3):164-6.

Three-year outcome of drug-eluting stent implantation for coronary artery bifurcation lesions.

Stinis CT, Hu SP, Price MJ, Teirstein PS.

Catheter Cardiovasc Interv. 2010 Feb 15;75(3):309-14.

Recent Publications 2010–2012

B-type natriuretic peptide assessment in ambulatory heart failure patients: insights from IMPROVE HF.

Ambrosy AP, Fonarow GC, Albert NM, Curtis AB, Heywood JT, Mehra MR, O'Connor CM, Reynolds D, Walsh MN, Yancy CW, Gheorghiade M.

J Cardiovasc Med (Hagerstown). 2012 Apr 2.

Lack of association between electronic health record systems and improvement in use of evidence-based heart failure therapies in outpatient cardiology practices.

Walsh MN, Albert NM, Curtis AB, Gheorghiade M, Heywood JT, Liu Y, Mehra MR, O'Connor CM, Reynolds D, Yancy CW, Fonarow GC.

Clin Cardiol. 2012 Mar;35(3):187-96. doi: 10.1002/clc.21971.

Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF.

Wilcox JE, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Heywood JT, Inge PJ, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Walsh MN, Gheorghiade M.

Am Heart J. 2012 Jan;163(1):49-56.e2.

Factors associated with improvement in guideline-based use of ICDs in eligible heart failure patients.

Mehra MR, Albert NM, Curtis AB, Gheorghiade M, Heywood JT, Liu Y, O'Connor CM, Reynolds D, Walsh MN, Yancy CW, Fonarow GC.

Pacing Clin Electrophysiol. 2012 Feb;35(2):135-45. doi: 10.1111/j.1540-8159.2011.03279.x. Epub 2011 Dec 6.

Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial.

Adamson PB, Gold MR, Bennett T, Bourge RC, Stevenson LW, Trupp R, Stromberg K, Wilkoff BL, Costanzo MR, Luby A, Aranda JM, Heywood JT, Baldwin HA, Aaron M, Smith A, Zile M.

Congest Heart Fail. 2011 Sep-Oct;17(5):248-54. doi: 10.1111/j.1751-7133.2011.00247.x. Epub 2011 Aug 10.

Modulation of novel cardiorenal and inflammatory biomarkers by intravenous nitroglycerin and nesiritide in acute decompensated heart failure: an exploratory study.

Chow SL, O'Barr SA, Peng J, Chew E, Pak F, Quist R, Patel P, Patterson JH, Heywood JT.

Circ Heart Fail. 2011 Jul;4(4):450-5.

Associations between outpatient heart failure process-of-care measures and mortality.

Fonarow GC, Albert NM, Curtis AB, Gheorghiade M, Heywood JT, Liu Y, Mehra MR, O'Connor CM, Reynolds D, Walsh MN, Yancy CW.

Circulation. 2011 Apr 19;123(15):1601-10. Epub 2011 Apr 4.

Renal function and neurohormonal changes following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure.

Chow SL, O'Barr SA, Peng J, Chew E, Pak F, Quist R, Patel P, Patterson JH, Heywood JT.

J Card Fail. 2011 Mar;17(3):181-7.

Stiff left atrial syndrome after catheter ablation for atrial fibrillation: clinical characterization, prevalence, and predictors.

Gibson DN, Di Biase L, Mohanty P, Patel JD, Bai R, Sanchez J, Burkhardt JD, Heywood JT, Johnson AD, Rubenson DS, Horton R, Gallinghouse GJ, Beheiry S, Curtis GP, Cohen DN, Lee MY, Smith MR, Gopinath D, Lewis WR, Natale A.

Heart Rhythm. 2011 Sep;8(9):1364-71. Epub 2011 Feb 23. Erratum in: Heart Rhythm. 2011 Nov;8(11):1828.

Recent Publications 2010–2012

Patient and practice factors associated with improvement in use of guideline-recommended therapies for outpatients with heart failure (from the IMPROVE HF trial).

O'Connor CM, Albert NM, Curtis AB, Gheorghiade M, Heywood JT, McBride ML, Inge PJ, Mehra MR, Reynolds D, Walsh MN, Yancy CW, Fonarow GC.

Am J Cardiol. 2011 Jan 15;107(2):250-8.

Equitable improvement for women and men in the use of guideline-recommended therapies for heart failure: findings from IMPROVE HF.

Walsh MN, Yancy CW, Albert NM, Curtis AB, Gheorghiade M, Heywood JT, Inge PJ, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Fonarow GC.

J Card Fail. 2010 Dec;16(12):940-9.

Direct left atrial pressure monitoring in severe heart failure: long-term sensor performance.

Troughton RW, Ritzema J, Eigler NL, Melton IC, Krum H, Adamson PB, Kar S, Shah PK, Whiting JS, Heywood JT, Rosero S, Singh JP, Saxon L, Matthews R, Crozier IG, Abraham WT; HOMEOSTASIS Investigators.

J Cardiovasc Transl Res. 2011 Feb;4(1):3-13. Epub 2010 Oct 14.

Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF).

Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Inge PJ, Mehra MR, O'Connor CM, Reynolds D, Walsh MN, Yancy CW.

Circulation. 2010 Aug 10;122(6):585-96.

Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF.

Heywood JT, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Gheorghiade M, Inge PJ, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Walsh MN.

Circ Heart Fail. 2010 Sep;3(5):596-605.

Outpatient cardiology practices with advanced practice nurses and physician assistants provide similar delivery of recommended therapies (findings from IMPROVE HF).

Albert NM, Fonarow GC, Yancy CW, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride M, Mehra MR, O'Connor CM, Reynolds D, Walsh MN.

Am J Cardiol. 2010 Jun 15;105(12):1773-9.

Influence of renal function on the use of guideline-recommended therapies for patients with heart failure.

Heywood JT, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Walsh MN.

Am J Cardiol. 2010 Apr 15;105(8):1140-6.

Electronic health records and quality of care for heart failure.

Walsh MN, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Fonarow GC.

Am Heart J. 2010 Apr;159(4):635-642.e1.

Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure.

Ritzema J, Troughton R, Melton I, Crozier I, Doughty R, Krum H, Walton A, Adamson P, Kar S, Shah PK, Richards M, Eigler NL, Whiting JS, Haas GJ, Heywood JT, Frampton CM, Abraham WT; Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients (HOMEOSTASIS) Study Group.

Circulation. 2010 Mar 9;121(9):1086-95.

Recent Publications 2010-2012

Influence of dedicated heart failure clinics on delivery of recommended therapies in outpatient cardiology practices: findings from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF).

Albert NM, Fonarow GC, Yancy CW, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride M, Mehra MR, O'Connor CM, Reynolds D, Walsh MN.

Am Heart J. 2010 Feb;159(2):238-44.

Adherence to guideline-recommended adjunctive heart failure therapies among outpatient cardiology practices (findings from IMPROVE HF).

Yancy CW, Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Walsh MN.

Am J Cardiol. 2010 Jan 15;105(2):255-60.

Is computed tomographic angiography prognostic in patients with cardiac symptoms?

Suhar CJ, Hitchcock TM, Russo RJ, Topol EJ.

J Am Coll Cardiol. 2008 Apr 15;51(15):1510; author reply 1510-1. No abstract available.

Salvage of pacemakers and automatic implantable cardioverter-defibrillators using dermis grafts.

Rudolph R, Smith MR, Curtis GP.

Ann Thorac Surg. 2011 Feb;91(2):452-6.

Pulmonary Vein Isolation for the Treatment of Drug-Refractory Atrial Fibrillation in Adults with Congenital Heart Disease.

Philip F, Muhammad KI, Agarwal S, Natale A, Krasuski RA.

Congenit Heart Dis. 2012 Apr 2.

Fragmented And Delayed Electrograms Within Fibro-Fatty Scar Predict Arrhythmic Events In Arrhythmogenic Right Ventricular Cardiomyopathy: Results from a Prospective Risk Stratification Study.

Santangeli P, Dello Russo A, Pieroni M, Casella M, Di Biase L, Burkhardt JD, Sanchez J, Lakkireddy D, Carbucicchio C, Zucchetti M, Pelargonio G, Themistoclakis S, Camporeale A, Rossillo A, Beheiry S, Hongo R, Bellocci F, Tondo C, Natale A. Heart Rhythm. 2012 Mar 29.

Impact of metabolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing catheter ablation.

Mohanty S, Mohanty P, Di Biase L, Bai R, Pump A, Santangeli P, Burkhardt D, Gallinghouse JG, Horton R, Sanchez JE, Bailey S, Zagrodzky J, Natale A.

J Am Coll Cardiol. 2012 Apr 3;59(14):1295-301.

Correlation Between Signal-Averaged Electrocardiogram and the Histologic Evaluation of the Myocardial Substrate in Right Ventricular Outflow Tract Arrhythmias.

Santangeli P, Pieroni M, Dello Russo A, Casella M, Pelargonio G, Di Biase L, Macchione A, Burkhardt JD, Bellocci F, Santarelli P, Tondo C, Natale A.

Circ Arrhythm Electrophysiol. 2012 Mar 15.

Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.

Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, Pimentel R, Mansour MC, D'Avila A, Sanchez JE, Burkhardt JD, Chalhoub F, Mohanty P, Coffey J, Shaik N, Monir G, Reddy VY, Ruskin J, Natale A.

J Am Coll Cardiol. 2012 Mar 27;59(13):1168-74.

Recent Publications 2010–2012

Drug-Refractory Ventricular Tachycardias Following Myocarditis: Endocardial and Epicardial Radiofrequency Catheter Ablation.

Dello Russo A, Casella M, Pieroni M, Pelargonio G, Bartoletti S, Santangeli P, Zucchetti M, Innocenti E, Di Biase L, Carbucicchio C, Bellocci F, Fiorentini C, Natale A, Tondo C.
Circ Arrhythm Electrophysiol. 2012 Jan 31.

The durability of pulmonary vein isolation using the visually guided laser balloon catheter: Multicenter results of pulmonary vein remapping studies.

Dukkipati SR, Neuzil P, Kautzner J, Petru J, Wichterle D, Skoda J, Cihak R, Peichl P, Dello Russo A, Pelargonio G, Tondo C, Natale A, Reddy VY.
Heart Rhythm. 2012 Jan 28.

Ablation of Atrial Fibrillation under Therapeutic Warfarin Reduces Periprocedural Complications: Evidence from a Meta-Analysis.

Santangeli P, Di Biase L, Horton R, Burkhardt JD, Sanchez J, Al-Ahmad A, Hongo R, Beheiry S, Bai R, Mohanty P, Lewis WR, Natale A.
Circ Arrhythm Electrophysiol. 2012 Jan 23.

Catheter ablation of atrial fibrillation: state-of-the-art techniques and future perspectives.

Santangeli P, Di Biase L, Burkhardt DJ, Horton R, Sanchez J, Bai R, Pump A, Perez M, Wang PJ, Natale A, Al-Ahmad A.
J Cardiovasc Med (Hagerstown). 2012 Feb;13(2):108-24.

Delayed cardiac tamponade after radiofrequency catheter ablation of atrial fibrillation: a worldwide report.

Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, Packer D, Ricci C, Skanes A, Ranucci M.
J Am Coll Cardiol. 2011 Dec 13;58(25):2696-7.

Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial).

Brugts JJ, Mercado N, Hu S, Guarneri M, Price M, Schatz R, Teirstein P, Wijns W, Serruys PW, O'Neill WW, Boersma E.
Am J Cardiol. 2009 Apr 1;103(7):917-22.

Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial).

Mercado N, Brugts JJ, Ix JH, Shlipak MG, Dixon SR, Gersh BJ, Lemos PA, Guarneri M, Teirstein PS, Wijns W, Serruys PW, Boersma E, O'Neill WW.
Am J Cardiol. 2008 Nov 1;102(9):1151-5.